Cartesian Therapeutics, Inc.
RNAC
Kedudukan dalam Saham
#18522
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.14
Modal Pasaran
$185.64M
Perubahan (1 hari)
-2.14%
Perubahan (1 tahun)
819.51%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Sejarah hasil dividen untuk Cartesian Therapeutics, Inc. (RNAC)
Hasil dividen (TTM) bagi Cartesian Therapeutics, Inc. (simbol saham: RNAC) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Cartesian Therapeutics, Inc. (RNAC) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
